Openbookopenbook
Equity
MaxCyte Inc(MXCT)
GBX --+0.00%
Reward46Moderate
Risk46Moderate
📊75%Data
Thin -111% profit margin · Revenue down 8% YoY
MXCT
+0.0 · +0.00%
GBX · LSE
MaxCyte Inc | Healthcare
Earnings Deterioration
Market Cap:161.75M
ℹ️
Reward Rating
46
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
46
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on MXCT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 537p.

What is MaxCyte Inc?

, a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.

MXCT · Verdict

Moderate reward · moderate risk

MXCT stands out on balance sheet and valuation, but watch the cash flow signal.

Based on 88% data coverage

MXCT · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet86/100

    Current ratio 10.88

  • Valuation65/100

    Above average

Watchouts 3

  • Cash flow25/100

    -76% free-cash-flow margin

  • Profitability35/100

    -106% net margin · -20% ROE

  • Growth42/100

    Rev -1.7% CAGR · earnings +7.9%

Model-based scoring. For information only — not financial advice.

What is MaxCyte Inc?

, a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 161.75M.

Financial Highlights

Investment Breakdown

📈 Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (46)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap161.75M
P/E RatioN/A
Dividend YieldN/A
52 Week High3.58
52 Week Low0.6434
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding106M
No. of Employees114
IndustryMedical Devices
ExchangeLSE
Beta1.041
CurrencyGBX · Reports in USD
Websitewww.maxcyte.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.